In re Lipitor Antitrust Litigation

Case Number:  12-cv-2389
Court:  District of New Jersey
Judge:  Peter J. Sheridan
Status:  Pending

Direct Purchaser Class Plaintiffs filed a lawsuit alleging that Pfizer and Ranbaxy violated federal antitrust laws by unlawfully impairing and delaying the introduction of generic versions of the prescription drug Lipitor into the United States market. Direct Purchaser Class Plaintiffs alleged that absent the unlawful conduct, Ranbaxy would have launched generic Lipitor earlier than November 30, 2011, the date on which Ranbaxy actually launched Lipitor. Direct Purchaser Class Plaintiffs allege that the prices for brand and generic Lipitor were higher than they would have been absent the challenged unlawful conduct.

Pfizer and Ranbaxy deny all of Direct Purchaser Class Plaintiffs’ allegations, including claims for damages or any other relief.

The litigation is pending in the United States District Court for the District of New Jersey before Judge Peter J. Sheridan.

On February 14, 2024, Direct Purchaser Class Plaintiffs filed a motion seeking certification of a settlement class, and preliminary approval for a proposed settlement of $93 million between Direct Purchaser Class Plaintiffs and Pfizer. Ranbaxy is not part of the proposed settlement. Direct Purchaser Class Plaintiffs’ claims against Ranbaxy remain pending.

On March 11, 2024, Judge Sheridan granted preliminary approval to the proposed settlement with Pfizer, and scheduled a fairness hearing for June 12, 2024.

The complaint against Pfizer and Ranbaxy, Direct Purchaser Class Plaintiffs’ proposed settlement with Pfizer, Judge Sheridan’s preliminary approval order, and associated documents, can be found in the links below.

Click document titles to open them.


  1. Complaint
  2. Direct Purchaser Class Plaintiffs' Unopposed Motion for Certification of a Settlement Class, Appointment of Lead Class Counsel, Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for Fairness Hearing
  3. Memorandum of Law in Support of Direct Purchaser Class Plaintiffs' Unopposed Motion for Certification of a Settlement Class, Appointment of Lead Class Counsel, Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for Fairness Hearing
  4. Declaration of Peter S. Pearlman in Support of Direct Purchaser Class Plaintiffs' Unopposed Motion for Certification of a Settlement Class, Appointment of Lead Class Counsel, Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for Fairness Hearing
  5. Exhibit 1 - Settlement Agreement
  6. Exhibit 2 - Proposed Plan of Allocation
  7. Exhibit 3 - Declaration of Jeffrey J. Leitzinger, Ph.D. Related to Proposed Allocation Plan and Net Settlement Fund Allocation
  8. Exhibit 4 - Declaration of William W. Wickersham of RG/2 Claims Administration in Support of Direct Purchaser Class Plaintiffs' Unopposed Motion for Certification of a Settlement Class, Appointment of Lead Class Counsel, Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for Fairness Hearing
  9. Proposed Order
  10. Order Granting Direct Purchaser Class Plaintiffs' Unopposed Motion for Certification of a Settlement Class, Appointment of Lead Class Counsel, Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for Fairness Hearing
  11. Notice of Settlement
  12. Claim Form
© Garwin Gerstein & Fisher LLP 2024  
88 Pine Street 10th Floor,
New York, NY 10005
Attorney Advertising  
Disclaimer   Diversity Policy